ReviewCurrent topics in microbiology and immunology2026
Human Papillomavirus Screening: Design and Targeting of Human Papillomavirus Genotypes.
Review in Current topics in microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2018, there were globally about 350,000 deaths from cervical cancer, despite the fact that the disease can be prevented by screening and in spite of the fact that highly effective human papillomavirus (HPV) tests became available some 25 years ago. WHO recommended HPV as the primary choice for cervical screening in 2014 (WHO 2014). In this chapter, I will outline the major evidence base behind HPV-based screening, discuss some of the major bottlenecks that has hampered the use of HPV-based screening for prevention of cervical cancer, and point out recent developments that may overcome these bottlenecks, in particular how targeting of screening to the most oncogenic HPV genotypes can be used to optimize sensitivity, specificity, and feasibility of HPV screening.
Indexed as
Identifiers
41691586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.